In 2026, the government is set to enhance measures encouraging the use of generic medicines in outpatient care, aiming to increase their market share to at least 55%, according to a joint proposal by the PSD and CDS-PP. This was approved today on the second day of the specialized voting on the State Budget for 2026 (OE2026).
The latest data released by Infarmed, related to 2024, indicate that the market share of generic medicines in outpatient settings reached 52.2%, marking a one-percent increase from 2023, setting a new record.
In hospitals, “the average usage rate of biosimilar medicines reached 82% in 2024, the highest annual figure recorded,” the pharmaceutical regulator reported.
